SBH
NARI

Segall Bryant & Hamill’s Inari Medical, Inc. Common Stock NARI Stock Holding History

Segall Bryant & Hamill’s Portfolio NARI Stock Details NARI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-120,635
Closed -$5.79M – 437
2024
Q1 		$5.79M Sell
120,635
-1,724
-1% -$92.1K 0.11% 247
2023
Q4 		$7.94M Buy
122,359
+403
+0.3% +$24.3K 0.15% 219
2023
Q3 		$7.98M Sell
121,956
-777
-0.6% -$48.9K 0.09% 249
2023
Q2 		$7.14M Buy
122,733
+567
+0.5% +$35.8K 0.07% 290
2023
Q1 		$7.54M Buy
122,166
+1,523
+1% +$91.4K 0.08% 271
2022
Q4 		$7.67M Buy
120,643
+8,368
+7% +$607K 0.09% 258
2022
Q3 		$8.15M Buy
112,275
+2,236
+2% +$166K 0.1% 244
2022
Q2 		$7.48M Buy
110,039
+32,739
+42% +$2.35M 0.08% 242
2022
Q1 		$7.01M Buy
77,300
+179
+0.2% +$14.7K 0.07% 260
2021
Q4 		$7.04M Buy
77,121
+37,611
+95% +$3.22M 0.07% 259
2021
Q3 		$3.2M Buy
39,510
+1,068
+3% +$89.7K 0.03% 411
2021
Q2 		$3.59M Buy
+38,442
New +$3.73M 0.03% 387

Other funds holding NARI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HCC Manager Chicago, Illinois $10.3M AUM 6.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Segall Bryant & Hamill's NARI Position: Q2 2024 in Review

Segall Bryant & Hamill sold out of Inari Medical, Inc. Common Stock (NARI) in Q2 2024, closing a stake of 120,635 shares — an estimated $5.79M sold.

Segall Bryant & Hamill first reported a position in NARI in Q2 2021 and held it in 12 quarters. The position peaked at $8.15M in Q3 2022. 243 funds tracked by Wall St. Rank hold NARI as of Q2 2024.

  • Segall Bryant & Hamill reported no remaining Inari Medical, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Segall Bryant & Hamill sold 120,635 Inari Medical, Inc. Common Stock shares in Q2 2024, an estimated $5.79M.
  • Segall Bryant & Hamill first reported a position in Inari Medical, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Segall Bryant & Hamill's Inari Medical, Inc. Common Stock position peaked at $8.15M in Q3 2022.
  • 243 funds tracked by Wall St. Rank held Inari Medical, Inc. Common Stock as of Q2 2024.

Based on Segall Bryant & Hamill's 13F filing for Q2 2024, filed 14 Aug 2024.